Updates on I/O Therapy for Non-Driver mNSCLC

A review of new FDA approvals in I/O therapy regarding a nivolumab/ipilimumab-based regimen as seen in the CheckMate 227 and CheckMate 9LA studies, along with considerations for immune-related adverse events.

Data from the following clinical trials are discussed:

• CheckMate 227: Nivolumab plus ipilimumab in advanced non–small cell lung cancer (Hellmann MD et al. N Engl J Med. 2019;381:2020-2031.)

• Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non–small cell lung cancer: Three-year update from CheckMate 227 Part 1. (Ramalingam SS et al. 2020 ASCO annual meeting. Abstract 9500.)

• Nivolumab + ipilimumab + 2 cycles of platinum-doublet chemotherapy vs 4 cycles chemo as first-line treatment for stage IV/recurrent non–small cell lung cancer: CheckMate 9LA. (Reck M et al. 2020 ASCO annual meeting. Abstract 9501.)

• IMpower110: Clinical safety in a phase III study of atezolizumab monotherapy vs platinum-based chemotherapy in first-line non–small cell lung cancer. (Jassem J et al. 2020 ASCO annual meeting. Abstract e21623.)